Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Xing, Yan ; Lin, Nancy U ; Maurer, Matthew A ; Chen, Huiqin ; Mahvash, Armeen ; Sahin, Aysegul ; Akcakanat, Argun ; Li, Yisheng ; Abramson, Vandana ; Litton, Jennifer ; Chavez-MacGregor, Mariana ; Valero, Vicente ; Piha-Paul, Sarina A ; Hong, David ; Do, Kim-Anh ; Tarco, Emily ; Riall, Dianna ; Eterovic, Agda Karina ; Wulf, Gerburg M ; Cantley, Lewis C ; Mills, Gordon B ; Doyle, L Austin ; Winer, Eric ; Hortobagyi, Gabriel N ; Gonzalez-Angulo, Ana Maria ; Meric-Bernstam, Funda

Breast cancer research : BCR, 2019-07, Vol.21 (1), p.78-78, Article 78 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível